ADAR1 Capital Management, LLC 13F holdings
ADAR1 Capital Management, LLC reported 261 positions with a total reported value of $2.1B as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: ABVX ABIVAX SA (11.4%), PTGX PROTAGONIST THERAPEUTICS INC (5.6%), ROIV ROIVANT SCIENCES LTD (5.3%), SPY STATE STR SPDR S&P 500 ETF T (4.6%), IMVT IMMUNOVANT INC (4.3%). Against 2026-03-31 it opened 39 new positions and exited 69. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when ADAR1 Capital Management, LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 261 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| ABVX ABIVAX SA | 1,804,703 | $240.5M | 11.4% |
| PTGX PROTAGONIST THERAPEUTICS INC | 960,863 | $117.8M | 5.6% |
| ROIV ROIVANT SCIENCES LTD | 3,157,008 | $111.7M | 5.3% |
| SPY STATE STR SPDR S&P 500 ETF T | 129,087 | $96.4M | 4.6% |
| IMVT IMMUNOVANT INC | 2,330,716 | $89.8M | 4.3% |
| ZLAB ZAI LAB LTD | 3,369,034 | $64.0M | 3.0% |
| AGIO AGIOS PHARMACEUTICALS INC | 1,288,053 | $47.8M | 2.3% |
| CRNX CRINETICS PHARMACEUTICALS IN | 1,222,080 | $45.7M | 2.2% |
| EA SERIES TRUST | 337,125 | $39.5M | 1.9% |
| CYTK CYTOKINETICS INC | 457,907 | $39.0M | 1.8% |
| SEPN SEPTERNA INC | 940,747 | $31.5M | 1.5% |
| AVR ANTERIS TECHNOLOGIES GLOBAL | 3,145,096 | $31.0M | 1.5% |
| EDIT EDITAS MEDICINE INC | 8,889,000 | $28.8M | 1.4% |
| DNLI DENALI THERAPEUTICS INC | 1,029,080 | $26.5M | 1.3% |
| SYRE SPYRE THERAPEUTICS INC | 283,982 | $25.2M | 1.2% |
| VIR VIR BIOTECHNOLOGY INC | 2,456,677 | $25.0M | 1.2% |
| PRAX PRAXIS PRECISION MEDICINES I | 74,253 | $24.9M | 1.2% |
| INSM INSMED INC | 228,520 | $24.4M | 1.2% |
| CLDX CELLDEX THERAPEUTICS INC NEW | 619,542 | $23.1M | 1.1% |
| VKTX VIKING THERAPEUTICS INC | 574,038 | $22.4M | 1.1% |
| TSHA TAYSHA GENE THERAPIES INC | 3,040,466 | $20.7M | 1.0% |
| MNPR MONOPAR THERAPEUTICS INC | 217,595 | $20.1M | 1.0% |
| OVID OVID THERAPEUTICS INC | 7,417,479 | $20.0M | 0.9% |
| ELVN ENLIVEN THERAPEUTICS INC | 387,718 | $19.7M | 0.9% |
| ENTA ENANTA PHARMACEUTICALS INC | 1,344,510 | $19.6M | 0.9% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 39 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| EDIT EDITAS MEDICINE INC | 8,889,000 | $28.8M | 1.4% |
| VOR VOR BIOPHARMA INC | 680,626 | $12.5M | 0.6% |
| FTH FAETH THERAPEUTICS INC | 361,010 | $9.0M | 0.4% |
| AMAN AMANAT ACQUISITION CORP | 750,000 | $7.6M | 0.4% |
| RACC RESEARCH ALLIANCE CORP III | 650,000 | $7.0M | 0.3% |
| RLAY RELAY THERAPEUTICS INC | 358,333 | $6.7M | 0.3% |
| DGAC DISCIPLINED GROWTH | 500,000 | $5.0M | 0.2% |
| BOLD BOUNDLESS BIO INC | 1,968,216 | $4.9M | 0.2% |
| AVLN AVALYN PHARMACEUTICALS INC | 146,447 | $4.8M | 0.2% |
| JATT JATT II ACQUISITION CORP | 417,724 | $4.7M | 0.2% |
| RNTX REIN THERAPEUTICS INC | 4,500,000 | $4.7M | 0.2% |
| APGE APOGEE THERAPEUTICS INC | 31,000 | $4.1M | 0.2% |
| SGMT SAGIMET BIOSCIENCES INC | 437,500 | $3.4M | 0.2% |
| CUE CUE BIOPHARMA INC | 55,193 | $1.7M | <0.1% |
| TRAX FIRST TRACKS BIOTHERAPEUTICS | 71,910 | $1.4M | <0.1% |
| INM INMED PHARMACEUTICALS INC | 800,000 | $1.2M | <0.1% |
| ARTV ARTIVA BIOTHERAPEUTICS INC | 118,624 | $1.2M | <0.1% |
| ALXO ALX ONCOLOGY HLDGS INC | 533,660 | $1.1M | <0.1% |
| RNAC CARTESIAN THERAPEUTICS INC | 98,877 | $1.0M | <0.1% |
| CYCLERION THERAPEUTICS INC | 298,757 | $1.0M | <0.1% |
| ACAD ACADIA PHARMACEUTICALS INC | 38,955 | $985.6K | <0.1% |
| GPCR STRUCTURE THERAPEUTICS INC | 17,500 | $939.2K | <0.1% |
| AURA AURA BIOSCIENCES INC | 130,152 | $924.1K | <0.1% |
| CHURCHILL CAP CORP XI | 50,000 | $872.5K | <0.1% |
| KZIA KAZIA THERAPEUTICS LTD | 61,550 | $866.6K | <0.1% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 69 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| TERNS PHARMACEUTICALS INC | 914,699 | $48.2M | 2.9% |
| BEAM BEAM THERAPEUTICS INC | 1,446,375 | $34.5M | 2.1% |
| SRRK SCHOLAR ROCK HLDG CORP | 407,273 | $20.0M | 1.2% |
| VERX VERTEX PHARMACEUTICALS INC | 15,075 | $6.7M | 0.4% |
| VIRIDIAN THERAPEUTICS INC | 304,422 | $6.0M | 0.4% |
| LLY ELI LILLY & CO | 5,060 | $4.7M | 0.3% |
| DNTH DIANTHUS THERAPEUTICS INC | 55,000 | $4.6M | 0.3% |
| BLTE BELITE BIO INC | 26,880 | $4.3M | 0.3% |
| ARCELLX INC | 32,084 | $3.7M | 0.2% |
| AVBP ARRIVENT BIOPHARMA INC | 141,814 | $3.3M | 0.2% |
| APELLIS PHARMACEUTICALS INC | 72,500 | $2.9M | 0.2% |
| MASIMO CORP | 15,000 | $2.7M | 0.2% |
| TFX TELEFLEX INCORPORATED | 21,186 | $2.5M | 0.2% |
| BIOA BIOAGE LABS INC | 135,560 | $2.4M | 0.1% |
| ALKS ALKERMES PLC | 46,400 | $1.6M | <0.1% |
| SOLENO THERAPEUTICS INC | 46,830 | $1.6M | <0.1% |
| CENTESSA PHARMACEUTICALS PLC | 38,566 | $1.5M | <0.1% |
| AMICUS THERAPEUTIC | 105,000 | $1.5M | <0.1% |
| UNH UNITEDHEALTH GROUP INC | 5,501 | $1.5M | <0.1% |
| SXT SENSIENT TECHNOLOGIES CORP | 15,000 | $1.3M | <0.1% |
| SDGR SCHRODINGER INC | 101,500 | $1.2M | <0.1% |
| FDMT 4D MOLECULAR THERAPEUTICS IN | 116,712 | $1.1M | <0.1% |
| DAY ONE BIOPHARMACEUTICALS I | 49,923 | $1.1M | <0.1% |
| BMY BRISTOL-MYERS SQUIBB CO | 17,500 | $1.1M | <0.1% |
| ARROWHEAD PHARMACEUTICALS IN | 10,000 | $1.0M | <0.1% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| ABVX ABIVAX SA | 1,394,019 | 1,804,703 | +29.5% | $240.5M |
| AGIO AGIOS PHARMACEUTICALS INC | 140,672 | 1,288,053 | +815.6% | $47.8M |
| SPY STATE STR SPDR S&P 500 ETF T | 75,940 | 129,087 | +70.0% | $96.4M |
| ZLAB ZAI LAB LTD | 1,425,367 | 3,369,034 | +136.4% | $64.0M |
| PRAX PRAXIS PRECISION MEDICINES I | 1,500 | 74,253 | +4,850.2% | $24.9M |
| INSM INSMED INC | 35,392 | 228,520 | +545.7% | $24.4M |
| ENTA ENANTA PHARMACEUTICALS INC | 51,357 | 1,344,510 | +2,518.0% | $19.6M |
| RLYB RALLYBIO CORP | 20,535 | 926,352 | +4,411.1% | $14.8M |
| VKTX VIKING THERAPEUTICS INC | 227,717 | 574,038 | +152.1% | $22.4M |
| QURE UNIQURE NV | 76,206 | 324,672 | +326.0% | $15.0M |
| ANL ADLAI NORTYE LTD | 117,909 | 1,017,805 | +763.2% | $11.7M |
| MAZE MAZE THERAPEUTICS INC | 50,095 | 339,276 | +577.3% | $10.1M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| DNLI DENALI THERAPEUTICS INC | 1,871,455 | 1,029,080 | -45.0% | $26.5M |
| CYTK CYTOKINETICS INC | 632,556 | 457,907 | -27.6% | $39.0M |
| IMVT IMMUNOVANT INC | 2,679,010 | 2,330,716 | -13.0% | $89.8M |
| MPLT MAPLIGHT THERAPEUTICS INC | 374,909 | 26,497 | -92.9% | $949.7K |
| SNY SANOFI SA | 316,939 | 57,100 | -82.0% | $2.4M |
| REPL REPLIMUNE GROUP INC | 1,582,987 | 655,784 | -58.6% | $7.3M |
| AMLX AMYLYX PHARMACEUTICALS INC | 1,000,604 | 494,378 | -50.6% | $8.9M |
| ABUS ARBUTUS BIOPHARMA CORP | 3,133,175 | 1,268,147 | -59.5% | $6.1M |
| RVMD REVOLUTION MEDICINES INC | 133,893 | 87,509 | -34.6% | $16.4M |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | 457,137 | 27,000 | -94.1% | $525.7K |
| RYTM RHYTHM PHARMACEUTICALS INC | 211,450 | 136,158 | -35.6% | $15.1M |
| DBVT DBV TECHNOLOGIES S A | 1,012,866 | 528,295 | -47.8% | $8.7M |
CIK 1940272 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
